| Document |
Document Title |
|
WO/2022/162471A1 |
Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
|
|
WO/2020/063999A1 |
Disclose herein are mono halogen or methyl-substituted 5-HT 2B antagonist compounds, which have been found with increased binding activity to 5-HT 2B receptor due to the substitution of halogen or methyl, and the method of using the comp...
|
|
WO/2020/055113A1 |
The present disclosure relates to an organic electroluminescent compound represented by formula 1 and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosu...
|
|
WO/2019/190212A1 |
According to the present invention, provided are: a compound applicable to an electron transport layer of an organic light-emitting diode; an organic light-emitting diode using the compound; and an organic EL display device comprising th...
|
|
WO/2019/092044A1 |
The present invention relates to the use of a compound of formula (I), to decrease or inhibit, in vitro or ex vivo, the Patched receptor drug efflux activity, in particular the chemotherapeutic drug efflux activity and chemotherapy resis...
|
|
WO/2013/161842A1 |
The invention pertains to a method for producing zaltoprofen or a zaltoprofen derivative by an intramolecular cyclization reaction of the Friedel-Crafts reaction type, wherein zaltoprofen or a zaltoprofen derivative is produced at an ind...
|
|
WO/2013/141264A1 |
The purpose of the present invention is to provide a novel compound with Eg5 inhibiting activity that is useful as an antitumoral agent. The present invention pertains to a compound expressed by the general formula (I) (in formula (I), A...
|
|
WO/2013/131521A1 |
The present application discloses an open-cage fullerene having a sulphur-containing 17 membered opening of the general formula : Xn@3, wherein X is selected from the group consisting of H2O, N2, H2, O2 and O3, and n is from 0 to 1; and ...
|
|
WO/2011/012987A1 |
The present invention relates to pharmaceutical compositions comprising rifampicin, piperine as a bioenhancer for rifampicin and isoniazid is in delayed release form, wherein the said pharmaceutical compositions have maintained bioavaila...
|
|
WO/2010/137620A1 |
Disclosed is a phenoxyethylamine derivative having an excellent selective α1D adrenergic receptor antagonistic activity. Specifically disclosed is a compound represented by formula (I) [wherein each symbol is as defined in the descripti...
|
|
WO/2010/070910A1 |
Disclosed is a 1-heterodiene derivative represented by the formula (2); or, a salt thereof. In formula (2), W represents a hydrogen atom or the like; A, an oxygen atom or the like; R1, a C1-6 alkyl group or the like that is unsubstituted...
|
|
WO/2009/152347A2 |
The invention relates to crystalline forms of zotepine hydrochloride, including the crystalline hydrochloride salt of zotepine and two cocrystals of zotepine hydrochloride with benzoic acid. The preparation and characterization of these ...
|
|
WO/2009/132832A2 |
The invention relates to a method for producing 1,4-benzothiepin-1,1-dioxide derivatives substituted with benzyl groups.
|
|
WO/2008/133288A1 |
Compounds represented by the general formula (1) or pharmacologically acceptable salts thereof; and squalene synthase inhibitors containing the same as the active ingredient: (1) (wherein R1 is phenyl which may be substituted with haloge...
|
|
WO/2008/109840A1 |
This invention is directed to, for example, compounds of formula (I): wherein n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically accep...
|
|
WO/2008/096755A1 |
Disclosed is a novel vanilloid receptor (VR1) inhibitor which can be used as an effective therapeutic agent for an acute pain and/or a chronic pain which has less adverse side effects and can be used safely. The vanilloid receptor (VR1) ...
|
|
WO/2008/065796A1 |
It is intended to provide an α-glucosidase inhibitor which is new and has a high activity. Accordingly, after a root or/and aerial part of Salacia reticulata is extracted with water, insoluble components are removed by adding ethanol. T...
|
|
WO/2008/058629A1 |
The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. These compounds are suitable, for example, as hypolipidemics.
|
|
WO/2008/061029A1 |
Compounds of formula (I) and pharmaceutically acceptable salt thereof, which are modulators of secreted frizzled related protein-1, are disclosed. The compounds, and compositions containing the compounds, can be used to treat various dis...
|
|
WO/2007/047737A1 |
Disclosed herein is a compound of Formula (I). Also disclosed herein is a method of modulating the activity of a cannabinoid receptor using a compound of Formula (I). Furthermore, disclosed herein is a method of treating a disease or con...
|
|
WO/2006/122776A1 |
The invention relates to substituted benzo-condensed cycloheptanone derivatives, to methods for producing them, to drugs containing said compounds and to the use of said compounds for producing drugs.
|
|
WO/2005/082874A1 |
It is intended to provide a drug useful as a remedy and a preventive for hyperlipemia; a drug also useful as a remedy and a preventive for liver disorders accompanying bile stasis, in particular, primary biliary cirrhosis, primary sclero...
|
|
WO/2005/079785A1 |
Preventive or therapeutic agents for hyperuricemia and/or gout which little produce adverse effect, containing as the active ingredient substances having both dibenzo[b,f]thiepin or dibenzo[b,f]oxepin skeletons and antioxidant substituen...
|
|
WO/2005/053676A1 |
The use of a pentadienoic acid derivative of formula (I) for the preparation of a medicament for the prevention or treatment of hyperuricemia and/or one or several associated disorders or diseases, and/or for reducing the serum uric acid...
|
|
WO/2005/011674A1 |
Preventive and/or therapeutic agents for bronchial asthma and tachykinin inhibitors, containing as the active ingredient tricyclic compounds represented by the general formula (I) or pharmacologically acceptable salts thereof: (I) wherei...
|
|
WO/2004/087131A1 |
Antitussives containing as the active ingredient tricyclic compounds represented by the general formula (I) or pharmacologically acceptable salts thereof: (I) wherein R1 is hydrogen, substituted or unsubstituted lower alkyl, or the like;...
|
|
WO/2004/076430A1 |
Compounds of formula: (I) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia are described. Processes...
|
|
WO/2004/064771A2 |
The present invention encompasses compounds of Formula I (I) or pharmaceutically acceptable salts thereof, wherein A is the base molecule of a propionic acid or acetic acid NSAID, or a derivative thereof, X is -CO2H, 1H-tetrazol-5-yl or ...
|
|
WO/2004/052847A2 |
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula...
|
|
WO2003022804A9 |
Among its several embodiments, the present invention provides an improved process for the preparation of tetrahydrobenzothiepine-1,1-dioxide compounds; the provision of a process for preparing a diastereomeric mixture of tetrahydrobenzot...
|
|
WO/2003/084961A1 |
The present invention relates to 1- or 3-thiabenzonaphthoazulene derivatives to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effect...
|
|
WO/2003/061604A2 |
Thiepine apical sodium co-dependent bile acid transport (ASBT) inhibitors are disclosed together with methods of making the same, methods of using the same to treat hyperlipidemic conditions as well as pharmaceutical compositions contain...
|
|
WO/2003/039255A1 |
A composition comprising a) compounds of formula (I):, wherein A−B denotes C−C or C=C&semi x is S, O, SO, SO2, NRa, or CRbRc&semi R1, R2 are H, halogen, OH, SH, NH2, CN, NO2, alkyl, alkoxy, alkylamino, dialkylamino, alkylthio, alke...
|
|
WO/2003/040127A1 |
Mono-fluorinated and di-fluorinated benzothiepine apical sodium co-dependent bile acid transport (ASBT) inhibitors are disclosed together with methods of making the same, methods of using the same to treat hyperlipidemic conditions as we...
|
|
WO/2003/027050A2 |
A process for preparing substituted pentacene compounds comprises the step of cyclizing substituted bis(benzyl)phthalic acids using an acid composition comprising trifluoromethanesulfonic acid, the substituted bis(benzyl)phthalic acids b...
|
|
WO/2003/022830A1 |
The present invention relates to compounds of formula (I) wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport ...
|
|
WO/2003/018024A1 |
The invention relates to mixtures of substances, containing propanolamine derivatives of formula I, in which the radicals have the indicated meanings, their physiologically acceptable salts and physiologically functional derivatives as w...
|
|
WO/2003/016245A1 |
The present invention is directed to the separation of enantiomers of racemates of formula (I). The separation proceeds by applying deemed racemates to continuos enantioselective chromatography like SMB. The methods predominantly is perf...
|
|
WO/2002/078625A2 |
The present invention provides therapeutic combinations and methods for treating or preventing a hypercholesterolemia-related or an inflammation -related condition in a subject in need of such treatment or prevention. One therapeutic com...
|
|
WO/2002/078626A2 |
The present invention provides therapeutic combinations and methods for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention. One therapeutic comb...
|
|
WO/2002/078710A1 |
Remedies for vesical hyperactivity which contain as the active ingredient tricyclic compounds represented by the following general formula (I) or pharmacologically acceptable salts thereof: (I) wherein R¿1? represents hydrogen, optional...
|
|
WO/2002/026856A1 |
An optical device comprises a substrate and at least one semiconductive polymer supported by said substrate, wherein said semiconductive polymer is a copolymer in which one of the repeat units is a group of formula (I) below or a homopol...
|
|
WO/2002/008218A1 |
The invention relates to cyclic substituted aminomethyl compounds of general formula IA and IB, methods for production thereof, intermediates in said production methods, a medicament containing at least one of said cyclic substituted ami...
|
|
WO/2001/068096A2 |
Novel methods and combinations for the treatment and/or prophylaxis of a hyperlipidemic condition or disorder in a subject, wherein the methods comprise the administration of one or more HMG Co-A reductase inhibitors and one or more ASBT...
|
|
WO/2001/068637A2 |
Among its several embodiments, the present invention provides an improved process for the preparation of tetrahydrobenzothiepine-1,1-dioxide compounds; the provision of a process for preparing a diastereomeric mixture of tetrahydrobenzot...
|
|
WO/2001/062244A1 |
Agents ameliorating body weight loss or anorexia in association with diseases such as liver diseases and agents ameliorating sickness behaviors. Preparations containing zaltoprofen as the active ingredient are used as agents ameliorating...
|
|
WO/2001/047889A1 |
Novel tricyclic compounds of general formula (I) or pharmacologically acceptable salts thereof, exhibiting leukotriene antagonism, wherein R?1¿ is halogeno or the like; R?2¿ is nitro or the like; A is a group derived from a five- or si...
|
|
WO/2001/032644A2 |
Compounds for formula (I) in which: Y represents O, NR?a¿, S, SO or SO¿2?; X?1¿ represents (CR?1¿R?2¿)m; X?2¿ represents (CR?3¿R?4¿)n; one of m and n is 1 and the other is 0 or 1; and R?1¿, R?2¿, R?3¿ and R?4¿ are each as def...
|
|
WO/2001/014360A2 |
This invention relates to new RAR selective retinoid agonists of formula (I) wherein the symbols are as defined in the specification to their pharmaceutically acceptable salts, individual isomers or to a racemic or non-racemic mixture; t...
|
|
WO/2000/075127A1 |
Compounds represented by general formula (1) or pharmaceutically acceptable salts thereof. In said formula, X is CH, CH¿2?, CHR (wherein R is lower alkyl or substituted lower alkyl), or CRR' (wherein R and R' are each as defined above a...
|
